Öz
Amaç: Bu çalışmada, biyolojik hastalığı modifiye eden antiromatizmal ilaçlar (b-DMARD) tedavisine başlayan romatoid artritli (RA) bireylerde kas ultrasonografisinin kullanımını araştırılmıştır.
Yöntem: RA tanısı almış ve henüz b-DMARD almamış toplam 56 kişi mevcut prospektif çalışmaya dahil edildi. Kontrol ve başlangıç kas gücü, fiziksel performans testleri, ultrasonografik kas parametreleri ve 40 hastadan oluşan bir grupta kontrollü koşullar altında hastalık aktivite skorları analiz edildi.
Bulgular: Rektus abdominis kasının kalınlığının, rektus femoris (RF) kasının kesit alanı (RFCSA), dış oblik kasının kalınlığı ve transvers abdominis kasının kalınlığı önemli iyileşmeler gösterdiği saptandı. Ek olarak, Klinik Hastalık Aktivitesi Indeksi puanları, remisyona ulaşan veya düşük hastalık aktivitesine sahip olanlarda RF kas kalınlığı, RFCSA ve gastrokinemius medialis kas kalınlığındaki yüzdelik değişimlerle istatiksel anlamlılık saptanmıştır.
Sonuç: Ultrasonografik kas görüntülemesi, RA hastalarının tedavisi sırasında klinisyene hastalık aktivite skorlarını izlemede yardımcı olabilir.
Anahtar Kelimeler: Romatoid artrit, b-DMARDs, kas, ultrasonografi
Kaynakça
Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244-57.
Amaya-Amaya J, Botello-Corzo D, Calixto OJ, et al. Usefulness of patients-re- ported outcomes in rheumatoid arthritis focus group. Arthritis. 2012;2012:935187.
Santo RCE, Fernandes KZ, Lora PS, et al. Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018;9: 816-25.
Yu S, Appleton S, Adams R, et al. The impact of low muscle mass definition on the prevalence of sarcopenia in older Australians. Biomed Res Int. 2014:2014:361790.
Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population- based sample of community-dwelling older adults. Journal of Cachexia Sarcopenia and Muscle 2016;7:290-8.
Hugo M, Mehsen-Cetre N, Pierreisnard A, et al. Energy expenditure and nutritional complications of metabolic syndrome and rheumatoid cachexia in rheumatoid arthritis: an observational study using calorimetry and actimetry. Rheumatology (Oxford). 2016;55:1202-9.
El Maghraoui A, Sadni S, Rezqi A, et al. Does rheumatoid cachexia predispose patients with rheumatoid arthritis to osteoporosis and vertebral fractures? J Rheumatol. 2015;42:1556-62.
van Bokhorst-de van der Schueren MA, Konijn NP, Bultink IE, et al. Relevance of the new pre-cachexia and cachexia definitions for patients with rheumatoid arthritis. Clin Nutr. 2012;31:1008-10.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31.
Kalyoncu U, Taşcılar EK, Ertenli Aİ, et al. Methodology of a new inflammatory arthritis registry: TReasure. Turk J Med Sci. 2018;48:856-61.
Singh H, Kumar H, Handa R, et al. Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience. Arthritis. 2011:2011:146398.
Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67:1360-4.
Miller MD, Ferris DG. Measurement of subjective phenomena in primary care research: the visual analogue scale. Fam Pract Res J. 1993;13:15-24.
Küçükdeveci AA, Sahin H, Ataman S,et al. Issues in cross-cultural validity: Example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004;51:14-9.
Ravens-Sieberer U, Wille N, Badia X, et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality Life Res. 2010;19:887-97.
Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. Journal Am Geriatr Soc. 1999;39:142-8.
Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14:531-2.
Bahat G, Yilmaz O, Kilic C, et al. Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging. 2018;22:898-903.
Kara M, Kaymak B, Ata AM, et al. STAR-sonographic thigh adjustment ratio: a golden formula for the diagnosis of sarcopenia. Am J Phys Med Rehabil. 2020;99:902-98.
Deniz O, Cruz-Jentoft A, Sengul Aycicek G, et al. Role of ultrasonography in estimating muscle mass in sarcopenic obesity. JPEN J Parenter Enteral Nutr. 2020;44:1398-406.
Esme M, Karcıoglu O, Oncel A, et al. Ultrasound assessment of sarcopenia in patients with sarcoidosis. J Ultrasound Med. 2022;41:951-9.
Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology. 2004;43:1219-23.
Ngeuleu A, Allali F, Medrare L, et al. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017;37:1015-20.
Katchamart W, Kieattisaksopon S, Narongroeknawin P, et al. Risk factors for sarcopenia in THAI patients with rheumatoid arthritis. Discov Med. 2023;35:436-43.
Kim J, Wang Z, Heymsfield SB, et al. Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr. 2002:76:378-83.
Gallagher D, Song M-Y. Evaluation of body composition: practical guidelines. Prim Care. 2003;30:249-65.
Bolanowski M, Nilsson BE. Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit. 2001;7:1029-33.
Buckinx F, Landi F, Cesari M, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 2018;9:269-78.
Perkisas S, Baudry S, Bauer J, et al. Application of ultrasound for muscle assessment in sarcopenia: towards standardized measurements. Eur Geriatr Med. 2018;9:739-57.
Pistilli EE, Jackson JR, Alway SE. Death receptor-associated pro-apoptotic signaling in aged skeletal muscle. Apoptosis. 2006;11:2115-26.
Sokka T, Häkkinen A, Kautiainen H, et al. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum. 2008:59:42-50.
Tekaya AB, Mehmli T, Ben Sassi M, et al. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023;42:979-97.
Vial G, Lambert C, Pereira B, et al. The effect of tnf and non-tnf-targeted biologics on body composition in rheumatoid arthritis. J Clin Med. 2021;10:487.
Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006;84:1463-72.
Santo RC, Silva JM, Lora PS, et al. Cachexia in patients with rheumatoid arthritis: a cohort study. Clin Rheumatol. 2020;39:3603-13.
Lemmey AB, Wilkinson TJ, Clayton RJ, et al. Tight control of disease activity fails to improve body com- position or physical function in rheumatoid arthritis patients. Rheumatology (Oxford). 2006: 55:1736-45.
